{
    "id": 13483,
    "fullName": "JAK2 R867Q",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "JAK2 R867Q lies within the protein kinase domain 2 of the Jak2 protein (UniProt.org). R867Q results in constitutive activation of STAT3/5, AKT and ERK signaling, and increased proliferation in thrombopoietin receptor-expressing cells in culture (PMID: 24398328).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 3844,
                    "pubMedId": 24398328,
                    "title": "Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24398328"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3717,
        "geneSymbol": "JAK2",
        "terms": [
            "JAK2",
            "JTK10",
            "THCYT3"
        ]
    },
    "variant": "R867Q",
    "createDate": "11/01/2015",
    "updateDate": "10/22/2019",
    "referenceTranscriptCoordinates": {
        "id": 150974,
        "transcript": "NM_004972",
        "gDna": "chr9:g.5089702G>A",
        "cDna": "c.2600G>A",
        "protein": "p.R867Q",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5586,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Jakafi (ruxolitinib) in culture (PMID: 24398328).",
            "molecularProfile": {
                "id": 13666,
                "profileName": "JAK2 R867Q"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3844,
                    "pubMedId": 24398328,
                    "title": "Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24398328"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5587,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to AZ960 in culture (PMID: 24398328).",
            "molecularProfile": {
                "id": 13666,
                "profileName": "JAK2 R867Q"
            },
            "therapy": {
                "id": 2786,
                "therapyName": "AZ960",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3844,
                    "pubMedId": 24398328,
                    "title": "Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24398328"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5588,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Momelotinib (CYT387) in culture (PMID: 24398328).",
            "molecularProfile": {
                "id": 13666,
                "profileName": "JAK2 R867Q"
            },
            "therapy": {
                "id": 823,
                "therapyName": "Momelotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3844,
                    "pubMedId": 24398328,
                    "title": "Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24398328"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5589,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Luminespib (AUY922) in culture (PMID: 24398328).",
            "molecularProfile": {
                "id": 13666,
                "profileName": "JAK2 R867Q"
            },
            "therapy": {
                "id": 647,
                "therapyName": "Luminespib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3844,
                    "pubMedId": 24398328,
                    "title": "Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24398328"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5585,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Inrebic (fedratinib) in culture (PMID: 24398328).",
            "molecularProfile": {
                "id": 13666,
                "profileName": "JAK2 R867Q"
            },
            "therapy": {
                "id": 911,
                "therapyName": "Fedratinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3844,
                    "pubMedId": 24398328,
                    "title": "Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24398328"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13666,
            "profileName": "JAK2 R867Q",
            "profileTreatmentApproaches": [
                {
                    "id": 7050,
                    "name": "JAK Inhibitor (Pan) - ATP competitive",
                    "profileName": "JAK2 R867Q"
                },
                {
                    "id": 7051,
                    "name": "JAK2 Inhibitor",
                    "profileName": "JAK2 R867Q"
                },
                {
                    "id": 7049,
                    "name": "JAK Inhibitor (Pan)",
                    "profileName": "JAK2 R867Q"
                },
                {
                    "id": 7052,
                    "name": "JAK2 Inhibitor - ATP competitive",
                    "profileName": "JAK2 R867Q"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 150974,
            "transcript": "NM_004972",
            "gDna": "chr9:g.5089702G>A",
            "cDna": "c.2600G>A",
            "protein": "p.R867Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 150973,
            "transcript": "NM_001322196",
            "gDna": "chr9:g.5089702G>A",
            "cDna": "c.2600G>A",
            "protein": "p.R867Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 150971,
            "transcript": "NM_001322194",
            "gDna": "chr9:g.5089702G>A",
            "cDna": "c.2600G>A",
            "protein": "p.R867Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 150972,
            "transcript": "NM_001322195",
            "gDna": "chr9:g.5089702G>A",
            "cDna": "c.2600G>A",
            "protein": "p.R867Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}